FDA approves the first drug for the neurological symptoms of Type 3 Gaucher disease
Infilbray, a daily pill that reaches the brain, improved a combined coordination and thinking score versus enzyme infusions in a 52-week trial of 43 patients. Survival was not the measure.

Read the original
The reporting lives at U.S. FDA. Our summary is checked against it, and we link it on every story.
The Food and Drug Administration on November 18, 2026, approved Infilbray (venglustat) tablets, the first treatment for the neurological symptoms of Type 3 Gaucher disease in adults and in children who weigh at least 15 kilograms, about 33 pounds. The agency said the pill crosses the blood-brain barrier and works as a glucosylceramide synthase inhibitor, slowing the buildup of fatty substances the body cannot break down. Type 3 disease, unlike type 1, affects the brain and can worsen balance, speech, memory, and thinking. The approval went to Genzyme Corporation, a Sanofi company, after orphan-drug designation and priority review.
The evidence is a randomized, double-blind study of 43 patients age 12 and older who were already stable on enzyme replacement therapy. For 52 weeks they took Infilbray once a day or continued intravenous enzyme therapy every two weeks. At week 52, the Infilbray group did better on a score that combined a coordination measure and a thinking measure. The FDA did not report a survival difference. The most common side effects were gastrointestinal symptoms and effects on mood. Serious psychiatric risks, including suicidal thoughts and behavior, have been reported. Animal studies flagged possible clouding of vision in younger patients and harm to a fetus if the drug is taken during pregnancy. The label has the full risk list.
Health & Tech in MarylandSilver Spring, MarylandMedical researchPublic healthGood news on November 18
More good news
Other stories in the same neighborhood of kindness.
Health & TechThe FDA approved Lembaz, the first drug shown to help infantile-onset Niemann-Pick C patients live longer
The FDA approved Lembaz, a spinal injection every two weeks. Among 36 treated patients, median survival was 8.5 years versus 4.9 in matched controls. It carries a boxed warning for hearing loss.
Verified · U.S. Food and Drug Administration
Health & TechFDA approves Roche's oral pill giredestrant for advanced breast cancer
The FDA approved giredestrant with everolimus for a specific advanced breast cancer. In a 207-patient trial it cut the risk of progression or death by 62%.
Verified · Reuters
Health & TechThe FDA approved a pre-surgery bladder cancer combo
The FDA approved durvalumab, sold as Imfinzi, plus enfortumab vedotin before bladder removal, then durvalumab afterward, for muscle-invasive bladder cancer in patients who cannot take cisplatin or who decline it. In the 695-patient VOLGA trial the combo cut the risk of an event by about half. It is not a cure.
Verified · U.S. Food and Drug Administration